New antibody drug takes on advanced cancers in first human trial
NCT ID NCT05378425
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called NTX-1088, which targets a protein on cancer cells, either alone or combined with the immunotherapy pembrolizumab. The study involves 90 people with advanced solid tumors that have spread or cannot be removed. The main goals are to find a safe dose and to see if the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NTX-1088 (a lab-made antibody targeting a protein on cancer cells) and pembrolizumab (an immunotherapy drug that helps the immune system attack cancer)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) and small study, so the drug may not shrink tumors or could cause side effects. Success in this trial does not guarantee it will work for most patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Hadassah Medical Center
Jerusalem, 9574425, Israel
-
Maria Skłodowska-Curie National Research Institute of Oncology
Warsaw, Poland
-
Ochsner Clinic Foundation
New Orleans, Louisiana, 70121, United States
-
Sheba Medical Center
Ramat Gan, 5262131, Israel
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States